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ABSTRACT 
The main objective of the study is to develop a design to formulate and characterize the 
nanoemulsion which is loaded with Bauhinia racemosa crude leaf extract. The leaves are 
found to possess thrombolytic activity. 
The nanoemulsion was prepared by using Tween 80, ethanol, cinnamon oil, distilled 
water in varying ratios of 2:1, 3:1, 4:1. The prepared nanoemulsion was then evaluated 
for particle size distribution, zeta potential, particle morphology, release study and 
stability studies. 
From these results it was concluded that the nanoemulsion containing particles was 
within the size range and also have a release profile that exhibit a uniform prolonged 
release pattern. 
Key words: Bauhinia racemosa, Nanoemulsion, solubility. 
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INTRODUCTION 
1.1 Nanoemulsion. [1,2] 
A controlled release drug delivery system can overcome some of the problems of conventional 
therapy and enhance the therapeutic effect of a given drug. To obtain maximum therapeutic 
safety and efficacy, it becomes necessary to deliver the agent to the target tissue in the optimal 
amount in the right period of time there by causing little toxicity and minimal side effects. There 
are various approaches in delivering a therapeutic substance to the target site in a sustained 
controlled release fashion. One such approach is using nanoemulsion as carriers for drugs. 
Nanoemulsions are submicron sized emulsions that are under extensive investigations as a drug 
carrier for improving the delivary of therapeutic agents. Nanoemulsions are by far most 
advanced nanoparticle system for the systemic delivary of biologically active agents for 
controlled drug delivary and targeting. Nanoemulsions are thermodynamicaly stable isotropic 
system in which two immiscible liquids (water and oil) are mixed to form a single phase by 
means of an appropriate surfactant or its mix with a droplet diameter of approximately 5nm -
200nm.Because of small size nanoemulsion are transparent.  
1.2 Types of nanaoemulsion. [3] 
 There are three types of nanoemulsion which can be formed: 
 (a) oil in water nanoemulsion in which oil is dispersed in the continuous aqueous phase,  
(b) water in oil nanoemulsion in which water droplets are dispersed in continuous oil phase,  
 (c) bi-continuous nanoemulsions where in micro domains of oil and water are interdispersed 
within the system. 
The main difference between emulsion and nanoemulsion are that even though emulsion is 
having kinetic stability they are thermodynamically unstable. Emulsions are cloudy but 
nanoemulsions are clear and translucent. They also differ in their method of preparation. 
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1.3 Advantages of nanoemulsion.[1] 
a. It may be used as substitute for liposomes and vesicles  
b. It improves the bioavailability of drug  
c. It is non-toxic and non-irritant in nature. 
d. It has improved physical stability. 
e. Nanoemulsions have small-sized droplets having greater surface area providing greater 
absorption. 
f. It can be formulated in variety of formulations such as foams, creams, liquids, and sprays. 
g. It provides better uptake of oil-soluble supplements in cell culture technology. 
h. It helps to solubilize lipophilic drug. 
i. Helpful in taste masking. 
j. Less amount of energy is required. 
1.4 Disadvantages of nanoemulsion. [4] 
a. Use of a large amount of surfactant and co-surfactant necessary for stabilizing the nano 
droplet 
b. Limited solubility capacity for high melting substance. 
c. The surfactant must be non toxic for pharmaceutical application. 
d. Nanoemulsion stability is influenced by environmental parameters such as temperature 
and pH. 
1.5 Components of nanoemulsion.[1] 
The main components of nanoemulsion are oil, emulsifying agents, and aqueous phases. 
 Oils can be of any type like castor oil, corn oil, coconut oil, evening primrose oil, linseed oil, 
mineral oil, olive oil, peanut oil, etc. A mixture of oil and water may yield a crude temporary 
emulsion, which upon standing, will separate in two distinct phases due to the coalescence of the 
dispersed globules. 
 Emulgents or emulsifying agents can impart stability to such systems. Emulgents are broadly 
classified as surfactants like spans and tweens, hydrophilic colloids such as acacia and finely 
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divided solids, e.g., bentonite and veegum. An emulgent, in addition to its emulsifying 
properties, should be nontoxic and its taste, odour and chemical stability should be compatible 
with the product. 
 Some of the desirable properties of an emulgent are: 
 (1) It should be able to reduce the surface tension to below 10 dynes/cm,  
(2) It should be adsorbed rapidly around dispersed phase globule to form a complete and 
coherent film to prevent coalescence, 
 (3) It should help in building up an adequate zeta potential and viscosity in the system so as to 
impart optimum stability, and 
 (4) It should be effective in a fairly low concentration.  
Emulgents form monomolecular, multimolecular or particulate films around the dispersed 
globules. 
1.5.1 Monomolecular films 
Surfactant type of emulgents stabilizes a nanoemulsion by forming a monolayer of adsorbed 
molecules or ions at the interface reducing interfacial tension. In modern day practice, 
combination of emulgents is preferred over single emulgent. The combination consists of a 
predominantly hydrophilic emulgent in the aqueous phase and a hydrophobic agent in the oily 
phase to form a complex film at the interface.  
1.5.2 Multimolecular films  
Hydrated lyophilic colloids form multimolecular films around globules of dispersed oil. 
Hydrated colloids do not cause any appreciable lowering of surface tension and their ability to 
form strong, coherent multimolecular films. Their tendency to increase the viscosity of the 
continuous phase enhances the stability of emulsion. 
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 1.5.3 Solid particulate films 
The emulgents forming particulate films are small solid particles that are wetted to some degree 
by both aqueous and non-aqueous liquid phases. They are concentrated at the interface where 
they produce a film around the dispersed globules thus preventing coalescence. 
1.6 Method of preparation of nanoemulsion. [5] 
Formulation of nanoemulsion includes active drug, additive and emulsifier. The 
various methods for the preparation of nanoemulsion include two methods:  
(a) high-energy emulsification and  
(b) low-energy emulsification.  
The high-energy emulsification method includes  
 high-energy stirring, 
 ultrasonic emulsification,  
 high-pressure homogenization, 
 microfluidization,  
 membrane emulsification  
The low-energy emulsification method includes  
 phase inversion temperature,  
 emulsion inversion point, and  
 spontaneous emulsification  
Using a combined method, which includes the high-energy and low-energy 
emulsification, it is possible to prepare reverse nanoemulsion in a highly viscous 
system. 
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1.6.1.a Ultrasonic Emulsification: 
Ultrasonic emulsification is very efficient in reducing droplet size. In ultrasonic 
emulsification, the energy is provided through sonotrodes called as sonicator probe. It 
contains piezoelectric quartz crystal which can expand and contract in response to 
alternating electric voltage. As the tip of sonicator contacts the liquid, it produces 
mechanical vibration and cavitation occurs. Cavitation is the formation and collapse 
of vapour cavities in liquid. Thus, ultrasound can be directly used to produce 
emulsion; it is mainly used in laboratories where emulsion droplet size as low as 0.2 
micrometer can be obtained. 
1.6.1.b High pressure homogenization: 
The preparation of nanoemulsion requires high-pressure homogenization. This 
technique makes use of high-pressure homogenizer/piston homogenizer to produce 
nanoemulsion of extremely low particle size (up to 1 nm). 
1.6.1.c Microfluidisation: 
Microfluidization is a patented mixing technology, which makes use of a device called 
microfluidizer. This device uses high pressure which forces the drug product through the 
interaction chamber resulting in a very fine particle of submicron range. The process is repeated 
several times to obtain a desired particle size to produce  uniform nanoemulsion. 
1.6.2.a Phase inversion temperature: 
This method involves change in phase by applying a higher temperature to a microemulsion  
1.6.2.b Spontaneous emulsification: 
It involves three steps: (a) preparation of homogeneous organic solution consisting of oil and 
lipophilic surfactant in water miscible solvent and hydrophilic surfactant, (b)stirring, o/w 
emulsion is formed, (c) the aqueous phase is removed by evaporation under reduced pressure. 
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1.7 EVALUATION OF NANOEMULSION [6] 
1.7.1 Droplet size analysis 
Droplet size analysis of nanoemulsion is measured by a diffusion method using a light-scattering, 
particle size-analyzer counter, LS 230. It is also measured by correlation spectroscopy that 
analyzes the fluctuation in scattering of light due to Brownian motion. Droplet size analysis of 
nanoemulsion can also be performed by transmission electron microscopy. 
1.7.2 Viscosity determination 
The viscosity of nanoemulsion is measured by using Brookfield-type rotary viscometer at 
different shear rates at different temperatures. 
1.7.3 Dilution test 
Dilution of a nanoemulsion either with oil or with water can reveal this type. The test is based on 
the fact that more of the continuous phase can be added into a nanoemulsion without causing the 
problem of its stability. Thus, an o/w nanoemulsion can be diluted with water and a w/o 
nanoemulsion can be diluted with oil. 
1.7.4 Drug content 
Preweighed nanoemulsion is extracted by dissolving in a suitable solvent, extract is analyzed by 
spectrophotometer or HPLC against standard solution of drug. 
1.7.5 Polydispersity 
It indicates the uniformity of droplet size in nanoemulsion. The higher the value of 
polydispersity, lower will be uniformity of droplet size of nanoemulsion. It can be defined as the 
ratio of standard deviation to mean droplet size. It is measured by a spectrophotometer. 
1.7.6 Dye test 
If a water-soluble dye is added in an o/w nanoemulsion the nanoemulsion takes up the colour 
uniformly. Conversely, if the emulsion is w/o type and the dye being soluble in water, the 
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emulsion takes up the colour only in the dispersed phase and the emulsion is not uniformly 
coloured. This can be revealed immediately by microscopic examination of the emulsion. 
1.7.7 Refractive index 
Refractive index of nanoemulsion is measured by Abbes refractometer. 
1.7.8 pH 
The pH of nanoemulsion can be measured by pH meter. 
1.7.9 Zeta potential 
Zeta potential is measured by an instrument known as Zeta PALS. It is used to measure the 
charge on the surface of droplet in nanoemulsion. 
1.7.10 Fluorescence test 
Many oils exhibit fluorescence when exposed to UV light. When a w/o nanoemulsion is exposed 
to a fluorescence light under a microscope, the entire field fluoresces. If the fluorescence is 
spotty, the nanoemulsion of o/w type. 
1.7.11 Percentage transmittance 
Percentage transmittance of nanoemulsion is measured by a UV-visible spectrophotometer. 
1.7.12 Conductance measurement 
The conductance of nanoemulsion is measured by a conductometer. In this test a pair of 
electrodes connected to a lamp and an electric source is dipped into an emulsion. If the emulsion 
is o/w type, water conducts the current and lamp gets lit due to passage of current between the 
electrodes. The lamp does not glow when the emulsion is w/o: oil being in external phase does 
not conduct the current. 
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1.7.13 Filter paper test 
This is based on the fact that an o/w nanoemulsion will spread out rapidly when dropped onto 
filter paper. In contrast, a w/o nanoemulsion will migrate only slowly. This method should not be 
used for highly viscous creams. 
1.7.14 In vitro Release Studies:  
The drug release rate from the nanoemulsion was carried out using the USP dissolution paddle 
assembly. A weighed amount of nanoemulsion equivalent to 100 mg drug were dispersed in 900 
ml of phosphate buffer 6.8 maintained at 37 ± 0.5°C and stirred at 100 rpm. At preselected time 
intervals one ml sample was withdrawn and replaced with equal amount of phosphate buffer 6.8. 
The collected samples were suitably diluted with phosphate buffer 6.8 and analyzed 
spectrophotometrically to determine the concentration of drug present in the dissolution medium. 
The dissolution studies were repeated using phosphate buffer pH 6.8 as dissolution medium. 
1.8 CIRCULATORY SYSTEM [7,8] 
 Human body contain various systems such as skeletal system, muscular system, circulatory 
system, nervous system, respiratory system, digestive system, excretory system, endocrine 
system, reproductive system and lymphatic system. Circulatory system plays main role and 
functions to transport nutrients, gases, hormones and waste throughout the body. 
 The circulatory system is divided, for descriptive purpose into two main parts. The blood 
circulatory system consisting of the heart which acts as a pump and the blood vessels through 
which the blood circulates. The lymphatic system consists of lymph nodes and lymph vessels 
through which colorless lymph flows. 
 The two systems communicate with one another and are intimately associated. The lungs 
(pulmonary circulation) oxygen absorbed and releases carbon dioxide. The rest of the body 
(systemic circulation) supplies oxygen and nutrition to the cells and removing waste products. 
The circulatory system (shown in Fig: 1) is involved in hemostasis as it ensures continuous  
supply of blood  to all body cells. Control of this system enables rapid response to change that 
affect delivery of adequate blood to the tissues. The supply of oxygen and nutrients to body cells 
becomes in adequate, hemostasis is threatened and tissue damage and death follows. Blood is 
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described as a connective tissue. It provides one of the means of communication between the 
cells of different parts of the body and the external environment. 
                      
                                             Fig: 1. The circulatory system. 
 Blood constitutes about 7 % of body weight. This proportion is less in woman and considerably 
greater in children. Blood in the blood vessel is always in motion. The flow is such that body 
cells have a fairly constant environment. Blood is composed of a straw colored transparent fluid 
called as plasma, in which different types of cells are suspended. Plasma constitutes about 55% 
and cells about 45% of blood volume. There are 3 types of cells such as 
 
Introduction 
 
R.V.S College of Pharmaceutical Sciences, Sulur Page 10 
 
 Erythrocytes (or) red blood cells 
 Leukocytes (or) white blood cells 
 Thrombocytes (or) platelets. 
All the blood cells originated from stem cells through several developmental stages before 
entering the blood. Erythrocytes are circular bi-concave non –nucleated disc with a diameter of 
about 7 micron (μ). They are formed in red bonr marrow present in the end s of the long bones 
and in flat and irregular bones. They pass through developmental stages before entering into 
circulation. Their life span is 120 days. 
Hemoglobin is a complex protein consisting of globin and an iron part called as haem and is 
synthesized inside the developing erythrocytes in red bone marrow. Haemoglobin in erythrocytes 
combines with oxygen to form oxy-haemoglobin giving blood its characteristic red color.  
Leukocytes have an important function in defending the body against microbes and other foreign 
materials. Leukocytes are the largest blood cells and they account for about 1% of the blood 
volume. They contain nuclei and some astemohave granules in their cytoplasm. 
Platelets are very small non-nucleated discs, 2-4 μ in diameter, derived from the cytoplasm of 
megakaryocytes in red bone marrow. They contain a variety of substances that promote blood 
clotting which causes hemostasis. 
Hemostasis is the process that maintains the blood within the blood vessels. It is a complicated 
but efficient mechanism interlocking responses of the blood vessels, the platelets, the coagulation 
factors and the fibrinolytic mechanism. Thrombogenesis coagulation of blood occurs in blood 
vessels that have not been injured, resulting in blockage of the concerned blood vessels leading 
to serious consequences. 
1.9 Clot formation [9] 
 The formation of clot involves several steps. A thrombus is formed at sites of injury, such as a 
simple skin laceration or miscellaneous intravascular injury. Circulating platelets first adhere to 
the site of injury and a series of events occurs that allows activation of these platelets. Activated 
platelets then recruit additional platelets to the site of injury where they aggregate to stabilize the 
plug until the body can provide further stability to the clot. Increased platelet activity and 
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vascular injury simultaneously stimulated previously inactive coagulation factors which are 
always present and circulating in normal blood. 
 Activation of these clotting factors results in the initiation of the intrinsic pathway, the extrinsic 
pathway or both. The intrinsic and extrinsic coagulation factor interactions take place and then 
converge at the same point, named the common pathway , the coagulation cascade continues, 
initiating a series of events that ultimately leads to the formation of an insoluble, stabilized fibrin 
clot. The formation of a thrombus takes place approximately 12-16 second in a normal 
individual. 
             
                                        Fig: 2. Stages of blood clot formation. 
 
1.10 Role of platelets and fibrin [10] 
        Platelets respond to the vascular trauma by an activation process which involves 3 steps 
 Adhesion to the site of injury 
 Release of intracellular granules 
 Aggregation of the platelets. 
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Platelets first adhere to exposed collagen in the sub-endothelial layers of injured blood vessels, 
triggering the release of platelet granules containing chemical mediators, which promote platelet 
aggregation and the formation of a plug composed of the viscous contents of lysed platelets. This 
rapidly arrests bleeding. Local stimulation of the coagulation cascade by factors released from 
the injured tissue and platelets results in the formation of thrombin. Thrombin, in turn, catalyzes 
the conversion of fibrinogen to fibrin, which is incorporated into the plug. Subsequent cross-
linking of the fibrin strands stabilizes the clot and forms a hemostasis plug . 
1.11 Thrombus versus embolus [10] 
  A clot that adheres to a vessel wall is called a thrombus, while an intervascular clot that floats 
within the blood is termed as embolus. Thus, a detached thrombus becomes an embolus. Both 
thrombi and emboli are dangerous , since they may occlude blood vessels and deprive tissues of 
oxygen and nutrients. Arterial thrombosis most often involves medium sized vessels rendered 
thrombogenic by surface lesions of endothelial cells caused by atherosclerosis. In contrast, 
venous thrombosis is triggered by blood or in-appropriate activation of the coagulation cascade, 
often as a result of a defect in the normal defense hemostasis mechanism. 
1.12 Types of thrombosis [11] 
         There are two distinct forms of thrombosis, each of which can be presented by several 
subtypes. 
1.12.1 Venous thrombosis 
Venous thrombosis is the formation of a thrombus within a vein. There are  several diseases that 
can be classified under this category. 
1.12.1.a Deep vein thrombosis 
Deep vein thrombosis is the formation of a blood clot within a deep vein. It is most commonly 
affects leg veins such as the femoral vein.Three factors are important in the formation of  a blood 
clot within a deep vein.These are the 
1. Rate of blood flow 
2. Thickness of the blood  
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3. Qualities of the vessel wall. 
Classical signs of deep vein thrombosis are included swelling, pain, redness of the affected area. 
1.12.1.b Portal vein thrombosis 
 Portal vein thrombosis is a form of venous thrombosis affecting the hepatic portal vein, which 
can lead to portal hypertension and reduction of the blood supply to the liver. It usually has a 
pathological cause such as pancreatitis, cirrhosis, diverticulitis or cholangiocarcinoma. 
1.12.1.c Renal vein thrombosis 
 Renal vein thrombosis is the obstruction of the renal vein by a thrombus. This tends to lead to 
reduced  drainage from the kidney. Anti coagulation therapy is the treatment of choice. 
1.12.1.d Jugular vein thrombosis 
Jugular vein is a condition that may occur due to infection, intravenous drug use or malignancy. 
Jugular vein thrombosis complications are including: 
1. Systemic sepsis 
2. Pulmonary embolism 
3. papilloedema 
Characterised by a sharp pain at the site of the vein, it is difficult to diagnose , because it can 
occur at random. 
1.12.1.e Budd chiari syndrome 
Budd chiari syndrome is the blockage of the hepatic vein or the inferior venacava. This form of 
thrombosis presents with abdominal pain , ascites and hepatomeagaly. Treatment varies between 
drug  therapy and surgical intervention using of shunts. 
1.12.1.f Paget schroetter disease  
Paget schroetter disease is the obstruction of an upper extremity vein (such as the axillary vein or 
sub clavian vein) by the thrombus. The condition usually comes to light after vigorous exercise 
and usually presents in younger, otherwise healthy people. Men are affected more than women. 
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1.12.1.g Cerebral venous sinus thrombosis 
Cerebral venous sinus thrombosis is a rare form of stroke which results from blockage of the 
dural venous sinuses by a thrombus. Symptoms are included headache, abnormal vision, any of 
the symptoms of stroke such as weakness of the face and limbs on one side of the body and 
seizures. The diagnosis is usually made with a computerized topography scan 
.12.2 Arterial thrombosis 
Arterial thrombosis is the formation of a thrombus  within an artery. In most cases, arterial 
thrombosis follows rupture of atheroma and is therefore reffered to as “atherothrombosis”. There 
are two diseases, which can be classified under this category: 
1.12.2.a Stroke  
A stroke is the rapid decline of brain function due to a disturbance in the supply of blood to the 
brain. This can be due to ischemia, thrombus, embolus (a lodged particle) or haemorrhage (a 
bleeding). In thrombotic stroke, a thrombus (a blood clot) usually forms around atherosclerotic 
plaques. Since blockage of the artery is gradual, onset of symptomatic thrombotic strokes is 
slower. Thrombotic stroke can be divided into two categories : 
1. Large vessel disease 
2. Small vessel disease 
The former affects vessels such as the internal carotids, vertebral and the circle of willis. The 
later can affect the smaller vessels such as the branches of the circle of willis. 
1.12.2.b Myocardial infraction  
Myocardial infraction is caused by an infract (death of tissue due to ischemia), often due to the 
obstruction of the coronary artery by a thrombus. Myocardial infraction can quickly become fatal 
if emergency medical treatment is not received promptly. If diagnosed within 12 hour (hr) of the 
initial episode (attack) then thrombolytic therapy is initiated. 
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1.13 Symptoms (www. Emedicine.com) 
Venous clot do not allow blood to return to the heart. Most often occurring in the legs or arms, 
symptoms include as follows: 
 Swelling 
 Warm 
 Redness 
 pain 
Arterial lots do not allow blood to get to the affected area. Body tissue that is deprived blood and 
oxygen begins to die and becomes ischemic. 
 Pain is the initial symptom of the ischemic, or oxygen deprivation due to loss of 
the blood supply. 
 Other symptoms depend upon the location of the clot often the effect will be a 
loss of function. Heart attack and stroke are self –explanatory. 
 In an arm or leg, in addition to pain, the limb may appear white and weakness, 
loss of sensation , or paralysis may occur. 
 If the blood supply is lost to an area of the bowel, in addition to intense pain, 
there may be bloody diarrhoea. 
1.14 Diagnosis [13] 
         The initial step in making the diagnosis of a blood clot is obtaining a patient history. The 
blood  clot a does not cause any problem but the location of the blood clot and its effect on blood 
flow that causes symptoms and signs. 
         If a blood clot or thrombus is a consideration, the history may expand to explore risk 
factors or situations that might put the patient at risk for forming a clot. Venous blood clots often 
develop slowly with a gradual onset of swelling, pain and discolouration. Symptoms of a venous 
thrombus will often progress over hours. Arterial thrombi occurs as an acute event. Tissues need 
oxygen immediately and the loss of blood supply creates a situation in which symptoms begin 
immediately.  
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         There may be symptoms that precede the acute artery blockage that may be the warnings 
signs of the potential future complete occlusion of the blood vessel. 
 Patients with an acute heart attack (myocardial infraction) may experience 
angina in the days and weeks prior to the heart attack. 
 Patients with peripheral artery disease may have pain with walking 
(claudication) and a transient ischemia attack, mini stroke may precede a 
stroke. 
Physical examination can assist in providing additional information that may increase the 
suspicion for a blood clot. 
1.14.1 Venous thrombi: 
   It may cause swelling of an extremity. It may be red, warm and tender  sometimes the 
appearance is difficult to distinguish from cellulitis or an infection of extremity. If there is a 
concern about a pulmonary embolus, the clinician may examine the lungs, listening to the 
abnormal sound caused by an area of inflamed lung tissue. 
1.14.2 Arterial thrombi: 
              The symptoms are much more dramatic. If a leg or arm is involved, the tissue may be 
white because of the lack of the blood supply. As well, it may be cool to touch and there may be 
a loss of sensation and movement. 
The patient may be writhing in pain. Arterial thrombus is all the cause of heart attack(myocardial 
infraction) and stroke(cerebro-vascular accident) and their associated symptoms. 
1.15. Drugs for the treatment of thrombosis: 
1.15.1 Anti-coagulation drugs [13] 
1.15.1.a Heparin 
Heparin (structure shown in Fig: 3) is a polysaccharide consisting of a chain of repeating 
sulphated disaccharide units of 60,000 – 100000 daltons. It is found in secretory granules of mast 
cells attached to a core protein. Heparin fragments reffered to as low molecular weight heparin 
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are used increasingly in the place un fractionated heparin. Heparin inhibits coagulation both in-
vivo and in-vitro by activating antithrombin III. Antithrombin III inhibits thrombin and other 
serine protease by binding to the serine site. Low molecular weight heparin increases the action 
of antithrombin III and factor Xa but not its action on thrombin, since the molecules are too 
small to bind to both enzymes and inhibitor essential for inhibition of thrombin but not for that of 
factor Xa. Heparin in higher doses interferes with platelets aggregation and prolongs bleeding 
time. 
 
                                           Fig: 3. Structure of Heparin 
 The standard intra venous schedule is usually 5,000 units loading intravenous followed by 1,000 
– 1,500 units per hour infusion by an infusion pump to give a total of 20,000 – 40,000 units per 
day to achieve an activated partial thromboplastin time of 1.5 – 2 times the control. Intermittent 
dosing can be done with an initial intravenous every 4 – 6 hour. Subcutaneous heparin in the 
dose of 5,000 units every 8 - 12 hour prevents post operative thrombo embolism. 
  The un-fractionated heparin is composed of sulfated polysaccharide molecules with a molecular 
weight range from 5,000 – 30,000 daltons and an average molecular weight of 12,000 – 15,000 
daltons. In the treatment of deep vein thrombosis, it has been found effective in a dose of 5,000 
units once daily. 
1.15.1.b Warfarin 
Warfarin (structure shown in Fig: 4 ) a coumarin derivative, inhibits clotting by limiting hepatic 
production of the biologically active vitamin K-dependent clotting factors (activated factors II, 
VII, IX, X).Normally the precursors of these factors under go a carboxylation rection to be 
coverted to their activated forms. Warfarin , as a vitamin K antagonist with this reaction.                                                         
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                                                 Fig: 4. Structure of Warfarin. 
The reduction in the amount and activity of these factors produces the anticoagulant response. 
However warfarin also interferes with production of the body’s natural anticoagulants, protein C, 
protein S. Peak plasma level is achieved between  2 – 8 hr after oral administration. They are 
highly bound to plasma protein (90 – 99%) principally to albumin. Sensitivity of anticoagulants 
varies from patient to patient and recquires individual adjustment of dose. 
Dose adjustments are done to keep a pro-thrombin time between 1.5 – 2 times and international 
normalized ratio 2 – 3 times of control. Loading dose of 10 –15 mg is followed by 1 – 10 mg per 
day maintenence dose. 
1.15.2 Anti-platelet drugs [14] 
The major role of antiplatelet drugs in clinical practice is to prevent the adverse clinical sequelae 
of thrombosis in atherosclerotic arteries to the heart (acute coronary syndrome),brain (ischaemic 
stroke), and limbs (inter-mittent claudication and rest pain) and thrombosis of stagnant blood in 
veins (venous thromboembolism) and heart chambers (atria fibrillation, heart failure). Dose and 
route of administration of anti-platelets drugs are in the Table no:1. 
1.15.2.a Aspirin 
Aspirin is chemically named as 2-acetoxybenzoic acid. It irreversibly inhibits prostaglandin H 
synthetase (cyclooxygenase-1) in the platelets and megakaryocytes and thereby blocks the 
formation of thromboxane A2(a potent vasoconstrictor and platelet aggregant). It is only parent 
form acetylsalicylic acid which has any significant effect on platelet function. Because platelets 
are unable to regenerate cyclooxygenase, the immediate anti-thrombotic effect of aspirin remains 
for the lifespan of the platelet (8-10 days). As, after stopping the aspirin therapy normal 
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hemostasis may be regained when about 20% of platelets have normal cyclooxygenase 
activity,daily aspirin intake is recommended. 
                                                          
                                                  Fig: 5. Structure of Aspirin. 
1.15.2.b Clopidogrel and ticlopidine 
The thienopyridine derivatives clopidogrel (structure shown in Fig: 6) and ticlopidine are 
metabolized in the liver to active compounds which covalently bind to the adenosine phosphate 
receptor on platelets and dramatically reduce platelet activation. 
                                    
                                         Fig: 6. Structure of clopidogrel. 
1.15.2.c Dipyridamole 
Dipyridamole (structure shown Fig:7) inhibits phosphodiesterase which inactivates cyclic 
adenosine monophosphate (AMP). Increased intraplatelet concentrations of cyclic AMP reduce 
the activation of cytoplasmic second messengers. Dipyridamole also stimulates prostacyclin 
release and inhibits thromboxane A2 formation. Because the effect is short-lasting , repeated 
dosing or slow-release preparations are recquired to inhibit platelet function for 24 hr. 
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                                               Fig: 7. Structure of Dipyridamole. 
1.15.2.d Glycoprotein IIb/IIIa receptor blockers. 
Glycoprotein IIb/IIIamreceptor antagonists block the final common pathway for platelet 
aggregation. Abciximab  is a humanized mouse antibody fragment with a high binding affinity 
for the glycoprotein IIb/IIIa receptor. Tirofiban (a non-peptide derivative of tyrosine) (structure 
shown in fig:8)  mimic part of the structure of fibrinogen that interacts with the glycoprotein 
IIb/IIIa receptor and thus compete with ligand binding of fibrinogen to the glycoprotein IIb/IIIa 
receptor. 
 
                     
                                                  Fig: 8. Structure of Tigrofiban. 
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                  Table: 1. Dose and route of administration of anti-platelet drugs. 
Drug  name  Dose  Route 
Aspirin Load: 160 mg 
Maintenance 75-150mg once 
daily. 
Oral 
Clopidogrel Load: 300mg 
Maintenance 75 mg once daily 
Oral 
Ticlopidine 250 mg twice daily Oral 
Dipyrimdamole 200 mg twice daily Oral 
Abciximab Bolus 250 (μg/kg) 
Infusion 0.125μg/kg/min 
Intravenous 30 min 
Infusion 24-72 hr 
Tirogiban Bolus 0.4- 0.6 μg/kg 
Infusion 0.10-0.15μg/kg/min 
Intravenous 1.2-1.6 hr 
Infusion 24-72 hr. 
 
1.15.3 Thrombolytic agents 
Thrombolytic drug dissolves blood clots by activating plasminogen, which forms a cleaved 
product called plasmin. Plasmin is a proteolytic enzyme that is capable of breaking cross-links 
between fibrin molecules, which provide the structural integrity of blood clots. Because of these 
actions, thrombolytic drugs are also called as “plasminogen activators” and “fibrinolytic drugs”. 
Thrombolytic agents are used to lyse already formed blood clots in clinical settings, where 
ischemia may be fatal (acute myocardial infraction, pulmonary embolism, ischemic stroke and 
arterial thrombosis). Very precise indications rule the use of these drugs,which are not free from 
serious side effects (bleeding). 
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1.15.3.a Tissue - type plasminogen activator 
Tissue-type plasminogen activator is a serine protease originally derived from cultured human 
melanoma cells, but it is now obtained in therapeutic quantities as a product of recombinant de-
oxyribo nucleic acid (DNA) technology. Tissue- type plasminogen has a low affinity for free 
plasminogen, but it rapidly activates plasminogen bound to fibrin in a thrombus or a hemostasis 
plug. Thus, tissue-type plasminogen is said to be fibrin selective and has the advantage of lysing 
only the fibrin, without unwanted degradation of  other proteins, notably fibrinogen. This 
contrasts with urokinase and streptokinase, which act on free plasminogen and induce a 
thrombolytic state. This advantage seems to be realized at low doses of tissue-type plasminogen, 
but at high doses a thrombolytic state is induced with the risk of hemorrhage. 
1.15.3.b Streptokinase 
Streptokinase (structure shown in Fig: 9) is an extracellular protein derived from purified culture 
broth of group C β-hemolytic streptococci. Streptokinase has no enzymatic activity; instead it 
forms an active complex with plasminogen, which then converts uncomplexed plasminogen to 
the active enzyme plasmin. In addition to the hydrolysis of fibrin plugs, the complex also 
catalyses the degradation of fibrinogen as well as clotting factors V and VII. It has half-life of 23 
min and for mocardical infraction. It is given in a dose of 7.5 -15 lakh units over 1 hr by 
intravenous infusion. 
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                                                Fig:9. Structure of Streptokinase. 
1.15.3. c Urokinase 
Urokinase is an enzyme capable of directly degrading both fibrin and fibrinogen. Urokinase was 
originally isolated from human urine, but it is now obtained from cultures of human fetal renal 
cells. Urokinase is more expensive than streptokinase and is usually employed in patients who 
are sensitive to streptokinase. It is not a foreign protein, therefore non-antigenic. For myocardial 
infraction, it is given in a dose of 2.5 lakhs units intravenous over a 10 min period followed by 5 
lakhs units over that 60min. 
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AIM AND OBJECTIVE 
 
Aim and objective of the study 
Thrombosis is the formation of an unwanted clot within a blood vessel or heart. It is the most 
common abnormality of hemostasis. Thrombolytic drugs are used to lyses blood clot. Blood clot 
can occur in any vascular bed, however, when they occur in coronary, cerebral, or pulmonary 
vessels, they can be immediately life threatening. Therefore, it is important to diagnose and treat 
rapidly thrombosis. 
On this regard, formulation of a natural thrombolytic drug with advanced technique of drug 
delivery for a safe and effective administration is the aim of this study. 
The main objective of the study is to  
 Prepare an extract of the dried aerial parts of the plant Bauhinia racemosa. 
 Acute toxicity study of the extract. 
 Determination of thrombolytic effect of the extract. 
 Preparation of the nanoemulsion of the plant extract.   
 Characterization of the nanoemulsion. 
 Stability study of nanoemulsion. 
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PLAN OF WORK 
 Extraction of the dried leaves of Bauhinia racemosa. 
 Acute toxicity study of the extract. 
 Gross behavior study. 
 Body weight analysis. 
 Hematological parameters. 
 Bio-chemical parameters. 
 Gross necropsy and histopathological studies. 
 Determination of thrombolytic activity of the extract. 
 Formulation of extract loaded nanoemulsion. 
 Evaluation and characterization of the prepared nanoemulsion. 
 Particle size distribution. 
 Zeta potential. 
 Particle morphology study. 
 In-vitro release study. 
 Stability study of the prepared nanoemulsion. 
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LITERATURE REVIEW 
3.1 Literature review for extraction method for Bauhinia racemosa leaves 
Sharanabasappa et al, (2007) conducted phytochemical study on Bauhinia racemosa. The 
leaves of the plant were shade dried, powdered, and then extracted with ethanol using soxhlet 
apparatus. 
Sunil nirmal et al, (2011) studied the antihistaminic effect of Bauhinia racemosa leaves in swiss 
albino mice. For this purpose the fresh leaves of the plant were shade dried, crushed to produce a 
coarse powder and subjected to extraction in a soxhlet apparatus using ethanol. The yield was 
reported to be 15.3% w/w. 
Pramila et al, (2014) conducted a study on biological activity of aqueous extract of some 
medicinal plants where in the fresh leaves of Bauhinia racemosa were collected shade dried  
powdered coarsely and then extracted with ethanol by using soxhlet apparatus. 
Ghumare pramila et al, (2014) carried out the preliminary phytochemical screening and anti 
bacterial activity of Bauhinia racemosa leaves. Aqueous, ethanol, chloroform, acetone and 
petroleum ether extracts of the leaves were prepared and its antibacterial activity was studied. It 
was concluded that the ethanol and acetone extracts showed good anti bacterial activity when 
compared to the other extracts. 
Kesavan et al, (2011) studied the pharmacological properties of Bauhinia racemosa leaf extract. 
The ethanol extract showed significant anti-diarrhoeal and anti inflammatory activity. The results 
obatained was comparable to the standard drug activity used. 
3.2 Literature review for in-vitro thrombolytic activity testing 
Mohammad mamun ur Rashid et al, (2014) carried out the in-vitro thrombolytic activity of 
methanolic extract of Protium serratum leaves where in the degree of lysis of the clot was found 
to be 59.65%, while the standard streptokinase and water used as positive and negative controls 
demonstrated 72.835 and 2.725 % of clot lysis respectively. 
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Mohammad Sekender Ali et al, (2013) studied the thrombolytic activity of methanolic extract 
of the  leaves of Adiantum philippense  by clot disruption method where the extract shows 
12.86%  and standard streptokinase shows 30.86% of clot lysis respectively. 
Md. Reyad-ul-Ferdous et al,(2014) carried out the thrombolytic activity with the methanolic 
extract of Bauhinia acuminate leaves and compared it to the standard drug streptokinase. It 
showed significant thrombolytic effect which was about 10.058%. 
Mohammad Shahadat Hossain et al, (2012) studied the in-vitro thrombolytic activity of 
ethanolic extract of Swertia chirata using the in-vitro clot lysis method.The crude ethanol extract 
was found to have a significant activity that showed a maximum effect of 40.38% while standard 
streptokinase showed 69.35%. 
Pushplata chougule et al, (2014) studied the in-vitro thrombolytic activity of ethanolic extract 
of leaves of Aegle marmelos. Here the study of thrombolytic activity of aegle marmalos was 
carried out by using a simple and quick in-vitro clot lysis method which exhibited a maximum 
clot lysis of 84% at 800 μg/ml of concentration in 90 mins of incubation at 37 C. Various 
concentrations of leaf extract i.e 200 μg/ml, 400 μg/ml, 800 μg/ml were tested at time intervals 
of 90 mins and incubation at 37° C for observing maximum clot lysis. The result findings 
indicated that concentration of leaf extract enhanced the percentage of clot lysis in dose 
dependent manner. Streptokinase and water were used as positive and negative control that 
showed clot lysis of 89% and 2% in 90 mins of incubation at 37° C respectively. 
Shah Md. Shahik et al, (2014) studied the in-vitro thrombolytic activity of Mentha spicata, 
Mentha virdis, Mentha arvensis. The study was carried out to check the clot lysis effect of the 
three plants where in streptokinase was used as a positive control and water as a negative control. 
The methanolic extract of the plant showed good thrombolytic acivity when compared with the 
ethanol, chloroform, acetone extract of the plants. 
Ramesh Londonkar et al, (2014) carried out the evaluation of in-vitro thrombolytic activity and 
cytotoxicity potential of Typha angustifolia leaf extracts. The methanol, aqueous and chloroform 
extracts were evaluated for the clot lysis effect. The extracts showed 58±2.32%, 
51.76±2.5%,18±1.84% of clot lysis, where as the positive control streptokinase 79.6±1.10% and 
negative control water 2.44±0.62% of clotlysis respectively. 
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3.3 Literature review for toxicity studies. 
Guimaraes et al, (2014) conducted a study on assessment of acute toxicity study of ethanolic 
extract of  Lychnophora pinaster. Acute toxicity of the crude ethanolic extract was evaluated by 
administration of the extract by oral route to male and female Swiss mice. A single extract dose 
of 125, 250 or 500 mg/kg was administered and the effects on spontaneous locomotor activity, 
exploratory behavior, muscle strength, body weight, food and water consumption, relative organ 
weight, histology, as well as hematological and biochemical parameters were evaluated. The 
three doses administered to the animals did not cause muscle tone alterations, but doses of 250 
and 500 mg/kg induced a significant inhibition of the spontaneous locomotor activity and 
exploratory behavior of the animals in open-field test. There was no alteration to hematological 
parameters and consumption of water and food, body weight variation and organs relative 
weight. Changes were observed in AST and ALT during assessment of biochemical parameters. 
The histopathological evaluation showed that the extract provoked cellular alterations, such as 
vacuolar degeneration and inflammation in kidneys and liver at all doses. Liver morphometric 
analyses of male and female mice showed that the extract did not have dose-dependent effects. 
Although females showed a significant increase in inflammatory cells, the effect was not dose-
dependent.  
R.K. Patel et al, (2012) carried out acute and sub acute oral toxicity evaluation of Benincasa 
hispida extract in rodents. The toxicity studies were carried out a 50% aqueous ethanolic extract 
of Benincasa hispida ( B. hispida )in rodents.The acute toxicity study, B. hispida was found to be 
well tolerated upto 2000mg/kg, produced neither mortality nor in behavior in mice. In subacute 
toxicity study, B.hispida at dose level of 200 and 400 mg/kg did not produce any significant 
difference in their body weight, food and water intake when compared to vehicle treated rats. It 
also showed no significant alteration in hematological and biochemical parameters in 
experimental groups of rats apart from a decrease in aspatate transaminase, alanine transaminase 
and alkaline phosphate content at the dose of 400 mg/kg. Histopathological study revealed 
normal architecture of kidney and liver of B. hispida treated rats. These results demonstrated that 
there is a wide margin of safety for the therapeutic use of B. hispida and further corroborated the 
traditional use of this extract as an anti hepatocarcinogenic agent. 
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Lalitha et al, (2013) carried out the acute oral toxicity studies of Anacyclus pyrethrum DC roots 
in albiono rats.  The present study was aimed to determine LD50 and to establish the safety of 
different solvents likewise petroleum ether, chloroform, ethyl acetate, acetone, ethanol, water 
extracts of Anacyclus pyrethrum DC (Asteraceae) root by acute oral toxicity study in female rats 
as per OECD guideline 423.  Rats were sequentially administered all the extracts in single 
dosages of 175, 550, and 2000 mg/kg of body weight. All the animals were individually studied 
for mortality, wellness parameters and body weight for 14 days. No mortality and no significant 
changes were observed in body weight and wellness parameters at 175, 550 and 2000 mg/kg 
body wt. doses, which reveal the safety of these extracts in the doses up to 2000 mg/kg body 
weight. Conclusively, LD50 value of A. pyrethrum DC root extracts was found to be more than 
2000 mg/kg body weight. 
Eugine et al, (2013) did the acute toxicity studies of andrographoloide. The present study has 
been designed with the objective to examine the andrographolide (isolated form A.paniculata) in 
order to evaluate its acute toxicities in experimental animal swiss albino mice. In acute toxicity 
studies the andrographolide 2000 mg/kg body weight was administered orally, observed after 
dosing and also observed for 14 days. Andrographolide effects on body weight, gross necropsy, 
hematological parameters, and biochemical parameters were studied. No significant variation in 
the body weight and organ weight between the control and the treated group was observed after 
single administration of andrographolide. Hematological and biochemical parameters of the 
control and the treated group revealed no toxic effect of the Andrographolide. No mortality was 
observed during 14 days study. From this study it may non-toxic through the oral route upto 
2000mg/kg body weight dose level. 
Abrar hussain mir et al, (2013) carried out an acute oral toxicity study of methanolic extract 
from Tridex procumbens in Sprague Dawley’s Rats as per OECD guidelines 423.The present 
study has been under taken to study the adverse or hazardous effects of methanolic extract from 
Tridex procumbens, dissolved in Dimethyl sulphoxide (DMSO) & accordingly to determine the 
LD50, to establish the safety of methanolic extract of Tridex procumbens in SD Rats as per 
OECD guidelines 423. All the Rats were sequentially administered orally the methanolic extract 
first in a single dosage of 2000 mg/kg body weight. All the animals were observed for mortality, 
wellness parameters and body weight for 14 days and due to some morbidity and mortality the 
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experiment was again performed at same dosage and same results were observed. Then decrease 
in the dosage to 300 mg/kg body weight was performed and accordingly observed as per OECD 
Guidelines 423. No mortality or any significant change was observed at 300 mg/kg body weight, 
however at 2000 mg/kg body weight dose the mortality rate was 2/3. Conclusively indicates the 
LD50 value of Tridex procumbens methanolic extract to be less than 2000 mg/kg body weight 
and more than 300 mg/kg body weight (LD50 ≥ 300 mg/kg body weight, but < 2000 mg/kg body 
weight). 
Oyemitan et al, (2013) carried out the acute toxicity , antinociceptive and anti-inflammatory 
activity of the essential oils of fresh fruits of Piper guineense Schum and Thonn in rodents. The 
study investigated the antiniciceptive and anti-inflammatory effect of the plant fruit volatile 
component and determines its acute toxicity profile in rodents in an attempt to rationalize the use 
of the plant in folkloric medicine. Essential oil of fresh fruits of  P.guineense obtained by 
hydrodistillation was emulsified with Tween 80 and was evaluated for acute toxicity test (LD50) 
through the oral (p.o) and intraperitoneal (i.p) routes in mice. The (LD50) values obtained were 
693 mg/kg (i.p) and 1265 mg/kg (p.o). This study shows that the essential oil of P.guineense was 
moderately toxic. 
Satish et al, (2013) carried out the acute toxicity study of Murraya koenigii. Acute toxicity study 
of Murraya koenigii was carried out against Swiss albino mice. Behavioural assessment and LD 
50 study was carried out. Results of present study shows that no mortality was observed at the 
highest dose level. The acute toxicity studies of crude powder (MCR) and methanol extract 
(MME) of Curry Leaves (Murraya koinigii) leave showed that they did not possess any toxic 
effect at the studied dose levels and are safe till the dose level of 9000 mg/ kg. 
 
3.4 Literature review for formulation of nanoemulsion 
Amudha et al, (2014) prepared and evaluated the self nanoemulsion containing Eclipta alba 
crude  extract. The emulsion was formulated by homogenization technique and evaluated for 
SEM, drug content and in-vitro diffusion study. From the results it was concluded that the self 
nano emulsion containing particles was at nanometric range and also the release characteristic 
studies shows an immediate better release pattern, so the self nano emulsion may enhance the 
solubility and bioavailability of herbal drugs. 
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Merrie Natalia et al, (2014) studied the physical stability and antibacterial activity of Nigella 
sativa oil nanoemulsion gel. This Nigella sativa oil also called as black cumin oil was formulated 
into nanoemulsion gel in various concentrations of 5%, 7%, 9%. Physical stability test was 
conducted by recording the effect of storage at room temperature, high and low temperature 
respectively, a centrifugation test and a cycling test. The results showed a yellow orange colored  
translucent  nanoemulsion gel was prepared with no phase separation and with a globule size of  
1 micrometer. The nanoemulsion gels were stable at room temperature and low temperature. 
Hayder Kadhim Drais et al, (2015) carried out the formulation and characterization of 
carvedilol nano emulsion oral liquid dosage form. The formulation components were chosen 
according to the solubility study. The diagrams of pseudo-ternary phase were made using the 
aqueous phase titration method. It was characterized by a low globule size range, acceptable low 
viscosity, low polydispersity index, higher zeta potential, good Ph value, efficient 
electroconductivity, classy percent of light transmittance, higher percentage drug content. 
Meenakshi sinha et al, (2015) had under taken the preparation and characterization of 
nanoemulsion based on carica papaya seed oil. Crude extract from the seeds of carica papaya 
induce variable responses depending on dose, duration and route of administration in laboratory 
animals. Nanoemulsion optimized formula were found at 75% water, 9% surfactant (tween 80), 
1% co-surfactant (span80) and 10% oil. The formulation was then characterized for droplet size, 
pH, TEM, zeta potential amd conductivity, in-vitro drug release. 
Caio P. Fernandes et al, (2015) had carried out the study on development and characterization 
of evening primrose (Oenothera biennis) oil nanoemulsion. Here the required hydroprophile-
Lipophile balance of evening primrose seeds oil was found to be 12. A stable nanoemulsion was 
formulated and characterized for mean droplet size, polydispersity index. 
Mukesh et al, (2014) had worked on the topic development and characterization of Boswellia 
serrata plant extract loaded nanoemulsion mixtures of for the treatment of anti inflammatory 
disorders. Here the spray dried Boswellia serrata extract was developed and charcterized to 
compare it in-vitro diffusion with reference formulation. Pseudo-ternary phase diagram was 
constructed by aqueous titration method, of which the evaluation method was improved for 
solubility, droplet size and transmittance. The optimized nanoemulsion consisted of isopropyl 
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myristate, tween 80 and ethanol (2:8:10 w/w ) and it remained stable for storing at 40°C, 4°C, 
25°C for atleast six months. The formulation was then evaluated for droplet size, zeta potential, 
structure morphology by TEM. 
Li Shupeng et al, (2011) carried out the work on preparation of w/o Astragulus polysaccharide 
Echinacea extract based nano emulsion and its amplified immune response. The formulation was 
optimized by the range of nanoemulsion zone in phase diagrams and the observations of naked 
eye. Its physicochemical properties were investigated including morphology, particle size 
distribution, pH, viscosity and stability. The formulation consisted of Tween 80, Span 80, 
paraffin oil, ethanol and water (with the volume ratio of 3:1:1.5:0.5:1) which was light yellow 
fluid. The particles were spherical under TEM, the viscosity and pH were 4.60s and 6.71 
respectively. 
Chutamas Uthumpa et al, (2013) developed a nanoemulsion formulation of ginger extract. The 
formulation was prepared from a mixture of oil phase (coconut oil and squalene), cremophor 
ELP, acetone and ginger extract by spontaneous emulsification method. Effect of coconut oil and 
squalene mass ratio on nanoemulsion formulations were evaluated further for the optimization of 
the system characterized by droplet size, polydispersibility index, zeta potential and Oswald 
ripening. Stability studies at 4°C and ambient temperatures for 3 months were performed and the 
formulation was found to be stable. 
Kumar et al, (2014) carried out a study on enhanced intestinal permeability of Tinosporia 
cardifolia stem extract through nanoemulsion formulation. The formulation was prepared by 
sonication-solvent evaporation method and optimized for encapsulation efficiency, release 
kinetics as well as stability parameters by pseudo-ternary phase diagram. Clove oil was used as a 
lipid phase while Span 80 and Tween 20 were used as surfactant. The optimized formulation 
consisted of clove oil, span 80, Tween 20 and ethanol (7.7:4:0.5:21w/w) and 83.8% of the 
extract. The nanoemulsion remained stable during the 3 months of the study. 
Heni Rachmawati et al, (2014) carried out the work on curcumin nanoemulsion for transdermal 
application: formulation and evaluation where in a nanoemulsion was formed by the self nano-
emulsification method, using an oil phase of glyceryl monooleate, cremaphor RH-40, poly 
ethylene glycol 400. Evaluation of the nanoemulsion include particle size analysis, 
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polydispersibility index, zeta potential, physical stability, raman spectrum and morphology. The 
spontaneously formed stable nanoemulsion had a capacity of 350 mg of curcumin / 10 gram of 
oil phase. Overall, the developed nanoemulsion system not only had an improved curcumin 
permeability but also protected the curcumin from chemical degradation. 
Marziyeh Khatibzadeh et al,(2014) had done their work on preparation of Azardirachta indica 
(neem) seed oil emulsion. In this study an attempt was made to prepare water based 
nanoemulsions from Neem seed oil using Tween 20 as a surfactant. Ultrasonic waves were used 
for applying shear to micro-scale droplets and altering them to nano-scale. Nanoemulsion with 
Neem oil and surfactant ratio of 1:4.5 which was sonicated for 45 minutes contained 50.21 nm 
droplets. 
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DRUG PROFILE 
5.1 Plant profile of Bauhinia racemosa [15] 
Vernacular names:  
Hindi   - katmauli 
Tamil            - atti 
Malayalam - arampalli, mandaram 
Telugu - tella arecettu 
Sanskrit         - yugmapatra 
Urdu              - Gul-e-anehal 
Taxonomical classification 
Kingdom -    Plantae 
Division          -    Angiosperma 
Class               -    Dicotyledonae 
 Order            -     Fabales 
Family            -     Caesalpiniaceae 
Genus              -    Bauhinia 
 Species           -     racemosa 
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                                               Fig 10. Bauhinia racemosa plant 
Botanical description 
Bauhinia racemosa is a small crocked tree with drooping branches, going up to 3-5 meters tall. 
Leaves are shaped like cow’s hooves (the typical Bauhinia like shape). They are broader than 
long 2-5*3-6 cms. Small flowers are borne in loose racemes 5-10 cm long. Flowers are greenish 
white in colour. Petals are 5 in number narrow lancelike, stamens 10 in number. Pods 13-25 cms 
by 1.8-2.5 cms in size, generally curved, swollen, rigid. Seeds 12-20 glabrous dark reddish 
brown or black , compressed 8mm long.  Flowering season : February - May 
Habitat 
Bauhinia raemosa grows abundantely in southeastern Asia : India, Pakistan, Srilanka, Cambodia, 
Myanmar, Thailand, Vietnam. It is usually grown from seeds in evergreen and deciduous forest 
areas and along the roadside and in villages. Any soil having fair amount of organic matter is 
suitable for commercial cultivation of this crop. 
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Plant parts used 
The aerial parts of the plant namely the leaf, flower, bark, fruit and bud are used to extract the 
active phytochemical constituent and thus used for its medicinal purpose. 
Phytochemistry 
A number of active constituents are found in Bauhinia racemosa like alkaloids, coumarins, 
apigenin, carbohydrates, flavanoids, quercetin, glycosides, protein, rutin, steroids, tannins. 
Uses 
It has a broad range of pharmacological action such as anti-asthmatic, anthelmentic, 
antibacterial, antiulcer, anti-malarial, astringent, antimicrobial, blood diseases, internal 
bleeding,ant-itumour, hepatoprotective ,anti HIV, antioxidant, anti-hyperglycemic. 
Excipient Profile 
5.2 Tween 80 [16] 
Chemical name : Polyoxyethylene 20 sorbitn mono oleate 
Molecular formula        :        C64H124O26        
Molecular weight          :        1310 g/mol 
Structure : 
                                  
                                                    Fig: 11.  Structure of Tween 80 
Description : 
Polysorbate has a characteristic odor and is warm, somewhat bitter in taste. It is soluble in 
ethanol, water, insoluble in mineral oil and vegetable oil. It should be stored in a well closed 
container, protected from light, in a cool, dry place. 
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5.3 Alcohol[16] 
Chemical name : ethanol 
Molecular formula        :        C2H6O      
Molecular weight          :        46.07g/mol  
Structure : 
 
                          
                                             Fig no:12. Structure of ethanol 
Description : 
Ethanol is produced by the fermentation of sugars by yeasts. It is a volatile, flammable, colorless 
liquid with a slight chemical odor. It is used as an antiseptic, a fuel, a solvent due to its low 
freezing point. The molecule is a simple one an ethyl group linked to a hydroxyl group. 
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5.4 Cinnamon oil [19] 
Cinnamomum cassia, called Chinese cassia or Chinese cinnamon, is an evergreen tree 
originating in southern China, and widely cultivated there and elsewhere in southern and eastern 
Asia (India, Indonesia, Laos, Malaysia, Taiwan, Thailand, and Vietnam). It is one of several 
species of Cinnamomum used primarily for their aromatic bark, which is used as a spice. In the 
United States, Chinese cassia is the most common type of cinnamon used. The buds are also used 
as a spice, especially in India, and were once used by the ancient Romans. 
The tree grows to 10–15 m tall, with greyish bark and hard, elongated leaves that are 10–15 cm 
long and have a decidedly reddish color when young. 
Cinnamomum cassia is a medicinal plant that contains cinnamic aldehyde. Studies of cinnamic 
aldehyde treatment in mid-aged rats have resulted in alleviation of chronic unexpected stress-
induced depressive-like behaviors. Cinnamic aldehyde is an enzyme inhibitor drug, immunologic 
drug, and an anti-inflammatory drug. It is administered orally to treat behavioral and mental 
disorders, targeting the hippocampus and the frontal cortex. Current findings might be beneficial 
in treating subjects in depression. 
Due to a blood-thinning component called coumarin, which could damage the liver if taken in 
huge amounts, European health agencies have warned against consuming high amounts of 
cassia. Other possible toxins founds in the bark/powder are cinnamaldehyde and styrene. 
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MATERIALS AND METHODS 
 
MATERIALS 
Table No: 2. List of chemicals with name of supplier 
S.No Name of the raw material Name of the supplier 
1 Tween 80 S D fine chemicals ltd, Mumbai 
2 Cinnamon oil Yucca enterprises, Mumbai 
3 Sodium dihydrogen 
orthophosphate 
Fine chemical industries, Chennai 
4 Di sodium hydrogen 
orthophosphate 
 S D fine chemicals ltd, Mumbai 
5 Di methyl sulphoxide Thermo electron LLS pvt ltd 
 
 
EQUIMENTS 
Table No: 3. List of equipments with company name 
S.No Name of the equipments Name of the supplier 
1 Hot air oven Texcare instruments 
2 Sonicator Vibronics ltd 
3 Centrifuge Remi instruments 
4 Zeta potential*  Malvern instruments 
5 Weighing balance  Essae - Teraoka ltd 
      6 Uv- spectrometer Lab India instruments 
7 Particle size analysis* Malvern instruments 
8 Magnetic stirrer Remi equipments 
9 SEM# Joel JSM,Japan 
 
*Zeta potential and Particle size analysis was obtained from PSG College of Pharmacy, 
Coimbtaore. 
# SEM was obatained from Nano science department, Bharatiyar university, Coimbatore. 
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6.1 Collection and identification of Bauhinia racemosa 
The plant materials (leaves) were collected from Sulur, Tamilnadu during the month of 
December 2016.  
6.2 Extraction of the leaves of Bauhinia racemosa [18,19,20,21,22] 
The leaves of Bauhinia racemosa were washed with water to remove the mud and other dust 
particals and then shade dried. These shade dried leaves was then coarsely powdered. 
Approximately 60 gm of drug powder was extracted with 500 ml ethanol using soxhlet apparatus 
for 8 hours by hot continuous method. The extract was then concentrated.  
6.3 Acute toxicity study of extract of Bauhinia racemosa [23,24,25,26,27,28,29,30] 
Inbreed wistar albino rats (200 -250 gm) was obtained from the animal house, RVS College of 
Pharmaceutical Sciences, Sulur. Animals were maintained in a room with controlled temperature 
(22 ± 2°C) for 12 hour (hr) light / 12 hour dark cycle with free access to food and water. Animal 
care and research protocols were based on the principles and guidelines adopted by the 
Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), 
India. The acute toxicity study was carried out in both the animals male as well as female wistar 
albino rats as per Organization Economic Cooperation Development (OECD 423) guidelines. 
For the evaluation of acute toxicity, the extract 2000mg/kg body weight was used. 
The animals were divided into four groups with three animals in each group. Prior to dosing, 
animals were fasted overnight before being weighed and the dose was administered orally by 
gavage  method. 
Control- animals received 1% w/v DMSO. 
Group 1 – minimum dose (500mg/ kg body weight suspended in 1% w/v DMSO) 
Group 2 – medium dose (1000 mg/ kg body weight suspended in 1% w/v DMSO) 
Group 3 – maximum dose (2000 mg/kg body weight suspended in 1% w/v DMSO) 
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6.3.1 Gross behavior study[31] 
The animals were continuously monitored for every 30 min for 3 hours (hr), 4th hr and 24th hr for 
gross behavioral changes and mortality. Once daily cage side observations included changes in 
skin, fur, eyes, autonomic nervous system (salivation, lacrimation and defecation) and central 
nervous system (ataxia, tremors and coma) changes. Mortality , if any was determined over a 
period of 14 days also recorded. 
6.3.2 Body weight analysis[32] 
Individual body weight of animal was recorded before the administration of a drug on 0 day of 
the study and the 14th day of the experiment before withdrawal of the blood from the individual 
animals. Changes in the body weight of the treated animals were compared with the control 
animals. 
6.3.3 Hematological study[33] 
Blood samples were collected by retro orbital puncture of all the treated animals and control 
animals. samples were analyzed for routine hematological parameters like hemoglobin, white 
blood corpuscle, red blood corpuscle, packed cell volume and platelet counts. Blood cell counts 
were done with blood smears. The above mentioned hematological parameters were analyzed. 
6.3.4 Biochemical study[32] 
For the determination of Serum Glutamic Oxaloacetate Transminase (SGOT), Serum Glutamic 
Pyruvate Transaminase (SGPT), total cholesterol, triglycerides, sugar, protein and creatinine, 
blood samples were collected separately for each of the group (control and treated) and then 
analyzed . 
6.3.5 Gross necropsy[31] and histopathological studies[34] 
After administration of drug at the end of 14th day, the animals were sacrificed by cervical 
dislocation method. All animals in the study were subjected to a full detailed gross necropsy like 
careful examination of the external surface of the body and abdominal cavities and their contents 
are examined. 
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The organs like liver, heart and kidney were dissected and washed with cold saline. All the tissue 
samples were fixed in 10% volume/volume (v/v) formalin and stained with hematoxylin and 
eosin stain for histopathological examination. All the tissue samples were examined under light 
microscopy.  
6.4 Determination of the thrombolytic activity of the extract[35,36,37,38,39,40,41,42] 
 The dry crude extract (1mg) was suspended in 1ml of DMSO. 1ml/tube of  blood was added into 
pre-weighed sterile micro centrifuge tube and incubated at 37°C for 45 mins. After clot 
formation, the serum was completely removed without disturbing the clot and each tube having 
the clot was again weighed to determine the clot weight. 
Clot weight = weight of clot containing tube – weight of tube alone 
To each micro centrifuge tube containing the pre weighed clot, 100μl DMSO solutions of 
different partitionates along with the crude extract was added separately. As, a positive control 
100μl of streptokinase (SK) and as a negative non thrombolytic control 100μl of distilled water 
and 100μl of DMSO were added separately to the different control tubes. All the tubes are then 
incubated at 37° C for 90 mins and observed for clot lysis. After incubation the released fluid 
was removed and the tubes were weighed again. The difference in weights taken before and after 
clot lysis were expressed as percentage of clot lysis as shown. 
% of clot lysis = (weight of released clot/ clot weight)* 100. 
6.5 Compatibility studies of the extract [43] 
6.5.1 Components screening by solubility determination  
One of the important factors to formulate a stable nanoemulsion system is choosing components  
of nanoemulsion which are oil, surfactants and co-surfactants. The components were selected by 
determining the solubility of the extract in different oils like coconut oil, neem oil, black cumin 
seed oil, cinnamon oil, soyabean oil; surfactants like tween 80, tween 20, span 80; co-surfactants 
like acetone, ethanol, methanol. 
1mg of the extract was dissolved in 1ml of the above mentioned exipients and the solubility was 
determined by visual observation with eyes. 
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6.5.2 Drug compatibility studies  
The physical stability of the excipient with drug extract has to be determined. The drug extract is 
mixed with the components used in the formulation in 1:1 ratio. These sample mixture is then 
placed in two closed containers each at room temperature 25±1°C and accelerated temperatures 
40±1°C for 8 weeks. The mixtures were then observed for any specific changes by visual 
observations. 
6.6 Preparation of nanoemulsion of the extract [44,45,46,47,48,49,50,51,52,53,54] 
Nanoemulsion was prepared by the ultrasonic emulsification method. Briefly, accurately 
weighed quantity of drug was dissolved in measured quantity of ethanol (co-surfactant). This 
was followed with the addition of measured amount of Tween 80 (surfactant). This mixture was 
called as Smix. By varying the concentration of surfactant and the co- surfactant various 
combinations of Smix ratios were prepared. The mixture was allowed to get homogenized 
properly by the help of an magnetic stirrer. To this cinnamon oil was added followed by required 
amount of distilled water and allowed to get a uniform, homogenized emulsion. This formed 
emulsion was then sonicated for 30 mins to get the nano emulsion. By, varying the Smix ratio as 
2:1, 3:1, 4:1and the concentration of oil and water 9 batches of nanoemulsion were formulated.  
                   
                                               Table no: 4. Formulation batches 
Sl.no Ingredients Formulation code 
F1 F2 F3 F4 F5 F6 F7   F8   F9  
1 Drug extract* 100      100      100       100      100      100      100      100        100 
2 Tween 80  40         40        40         40      52.5     52.5     52.5      64          64 
3 Ethanol   20        20        20         20      17.5    17.5     17.5       16         16 
4 Cinnamon oil   20        15        10          5         15      10          5         10           5 
5 Distilled water   20         25        30         35       15       20        25        10          15 
 
 * Marked values are in milligrams. All other values are in ml. 
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6.7Characterization of prepared nanoemulsion 
6.7.1 Particle size analysis [49] 
For the determination of particle size optical microscopy method was employed. The particle 
size distribution studies of the nanoemulsion was carried out using particle size analyzer (Particle 
size analyzer Hydro 2000 SM, Malvern Instruments, UK). 
10 ml of the sample is dispersed in 120 ml of dispersion medium and analysis was performed at a 
scattering angle of 90° and at a temperature of 25°C for particle size analyzer. For the 
measurement of particle size by zeta seizer, each sample (1-2 ml) was placed in a disposable zeta 
cell and run to obtain the zeta size value at 25°C. The analysis was performed thrice and the 
average value was reported. 
6.7.2 Zeta potential determination [50] 
Zeta potential values of nanoemulsion was determined by using zeta sizer version 6.2 (Malvern 
Instruments, UK). The nanoemulsion (1 ml) was dispersed in a disposable zeta cell. Palladium 
electrode was inserted in distilled water in the cuvette and the analysis was performed at 25°C. 
All  the measurements were done in triplicate and average value was reported , which measures 
the distribution of the electrophoretic mobility of particles using the laser Doppler velocity 
technique. The analyzer calculated the zeta potential from the measured velocity using the 
smoluchowski equation. 
6.7.3 Particle morphology study [49] 
2ml of nanoemulsion was placed on stub and dried for overnight under room temperature. Prior 
to loading the samples for taking the photomicrograph, samples are coated with a an electron 
dense coating materials like gold, palladium or a combination of both, to enhance the signal 
emitted by the sample by providing heavy metal atoms with incident beam of an electronand to 
conduct the accumulated sample charge and heat to the sample holder. The coating process was 
either carried out using sputter coating or thermal vacuum evaporation. 
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6.7.4 In vitro release study [49] 
In vitro diffusion studies was performed for all the formulated batches using a dialysis technique. 
The dialyzing medium was phosphate buffer ph 7.4. One end of pretreated cellulose dialysis 
tubing (7 cm in length) was tied with thread and then 1 ml of self nano emulsifying formulation 
was placed in it along with 0.5 ml of dialyzing medium. The other end of the tubing was also 
securecd with thread and was allowed to rotate freely in 200 ml of dialyzing medium and stirred 
continuously at 100 rpm with magnetic bead on magnetic plate 37°C. Aliquots of 1 ml were 
removed at different time intervals and diluted further with the buffer. 
Volume of aliquots was replaced with fresh dialyzing medium each time. These samples were 
analyzed quantitatively for drug dialyzed across the membrane at corresponding time by using 
UV- visible spectrophotometer. 
6.8 Stability study of nanoemulsion [52] 
The stability of prepared nanoemulsion was tested by subjecting them to different stress 
conditions of mechanical and accelerated temperatures. The prepared formulations were 
evaluated for the following attributes: 
6.8.1 Mechanical stress study 
The different formulations were centrifuged at 2000 rpm for different intervals and noted the 
volume of phase separation of nanoemulsion. 
6.8.2 Accelerated temperature study 
The phase separation study was performed for the evaluation of prepared formulations by storing 
them at different accelerated temperatures. Three batches of the same formulations were stored 
in sealed and scaled containers at room temperature (25 ± 1°C), at refrigerated temperature (4 ± 
1°C) and at higher temperature (40 ± 1°C) for 30 days. After 1, 10, 20 and 30 days each 
formulation was evaluated by visual observation for phase separation 
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RESULTS AND DISCUSSION 
7.1 Collection and identification of Bauhinia racemosa 
The plant materials (leaves) were collected from Sulur, Tamilnadu during the month of march 
2016. It was authenticated by Dr. M. Palanisamy, Scientist ‘D’, In charge Botanical Survey of 
India, Southern Regional Centre, Coimbatore, Tamilnadu – 641003. Register No: 
BSI/SRC/5/23/2016/Tech./585. 
7.2 Extraction of the leaves of Bauhinia racemosa 
Extraction of the leaves of Bauhinia racemosa was carried out as per the procedure given under 
materials and methods section 6.2. 
The dried leaves powder approximately 60 gm was extracted with 500 ml of ethanol for 8 hours 
(hrs) by hot continuous extraction method by using soxhlet apparatus. The extract was 
concentrated. The yield was found to be 15.95% w/v. 
7.3 Acute toxicity study of extract of Bauhinia racemosa 
Acute toxicity study was carried out as per the procedure described in materials and methods 
section 6.3. 
During the study period of 14 days, there was no mortality or morbidity observed in the 
experimental animals followed by single oral administration of extract. 
7.3.1 Gross behavior study 
Gross behavior study was carried out as per the procedure described in materials and methods 
section 6.3.1 
The results of the study revealed no adverse change in cage side observation in animals. The 
results are shown in the Table no: 5, 6 and 7. All the animals in the control and treated groups 
were found healthy as well as active. 
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Table no: 5. Gross behavior study of treated animals. (Group - 1. Minimum dose) 
Observation 0.5 hr 1.0 hr 1.5 hr 2.0hr 2.5 hr 3.0 hr 4.0 hr 24 hr 
Skin and Fur + + + + + + + + 
Ear + + + + + + + + 
Eyes + + + + + + + + 
Salivation + + + + + + + + 
Diarrhoea _ _ _ _ _ _ _ _ 
Lacrimation _ _ _ _ _ _ _ _ 
Ataxia _ _ _ _ _ _ _ _ 
Tremors _ _ _ _ _ _ _ _ 
Coma _ _ _ _ _ _ _ _ 
Mortality _ _ _ _ _ _ _ _ 
 
Table no: 6. Gross behavior study of treated animals. (Group - 2. Medium dose) 
Observation  0.5 hr 1.0 hr 1.5 hr 2.0 hr 2.5 hr 3.0 hr 4.0 hr 24 hr 
Skin and fur + + + + + + + + 
Ear + + + + + + + + 
Eyes + + + + + + + + 
Salivation + + + + + + + + 
Diarrhea _ _ _ _ _ _ _ _ 
Lacrimation _ _ _ _ _ _ _ _ 
Ataxia _ _ _ _ _ _ _ _ 
Tremors _ _ _ _ _ _ _ _ 
Coma _ _ _ _ _ _ _ _ 
Mortality _ _ _ _ _ _ _ _ 
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Table no: 7. Gross behavior study of treated animals. ( Group – 3. Maximum dose) 
Observation  0.5 hr 1.0 hr 1.5 hr 2.0 hr 2.5 hr 3.0 hr 4.0 hr 24 hr 
Skin and Fur + + + + + + + + 
Ear  + + + + + + + + 
Eyes + + + + + + + + 
Salivation + + + + + + + + 
Diarrhea _ _ _ _ _ _ _ _ 
Lacrimation _ _ _ _ _ _ _ _ 
Ataxia _ _ _ _ _ _ _ _ 
Tremors _ _ _ _ _ _ _ _ 
Coma _ _ _ _ _ _ _ _ 
Mortality _ _ _ _ _ _ _ _ 
 
[   + Normal   - Absence] 
The control animals were also observed and there was no change in the above parameters. 
7.3.2 Body weight analysis 
Body weight analysis was carried out as per the procedure described in materials and methods 
section 6.3.2. 
No considerable changes were observed in the body weight between the groups and the data are 
tabulated in Table no: 8. 
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Table no : 8. Effect of  leaf extract on body weight. 
Groups Body weight (gm) on day 0 
(n=3) 
Body weight (gm) on day 
14(n=3) 
 Control 178.66 ± 6.02 176.00 ± 3.60 
 Group – 1 (minimum dose) 174.66 ± 4.51 173.33 ± 1.53 
 Group – 2 (medium dose) 206.33 ± 6.02 201.66 ± 8.08 
 Group – 3(maximum dose) 238.00 ± 7.54 236.00 ± 3.60 
 
Fig no: 14. Effect of leaf extract on body weight. 
 
         
 
7.3.3 Hematological study 
Determination of the hematological parameters were carried out as per the procedure described 
in materials and methods section 6.3.3. 
All hematological parameters of test group was compared to that of the control group. There 
were no significant changes in the tested hematological parameters like 
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 Hemoglobin (Hb) 
 White Blood Corpuscle (WBC) 
 Red Blood Corpuscle (RBC) 
 Packed Cell Volume (PCV) 
 Platelet counts. 
The results are shown in Table no: 9. 
         Table no: 9. Effect of leaf extract on hematological parameters 
Parameters 
 
Control group 
(n=3) 
 Group – 1 
(minimum 
dose). (n=3) 
Group -2 
(medium dose). 
(n=3) 
Group-3 
(maximum 
dose). (n=3) 
Hb (g %) 13.76 ± 0.44 13.36 ± 0.61 13.03 ± 03 14.23 ± 0.30 
WBC (103/ cubic 
millimeter) 
12.3 ± 0.4 13.2 ± 0.3 11.7 ± 0.65 12.23 ± 0.45 
RBC          
(106/cu mm) 
5.71 ± 0.07 5.44 ± 0.187 5.37 ± 0.40 5.73 ± 0.04 
PCV (%) 43.8 ± 1.80 42.26 ± 0.40 40.63 ± 0.84 43.56 ± 0.90 
Platelets        
(103/ cu mm) 
852.33 ± 11.67 703.33 ± 12.58 817.33 ± 12.74 895 ± 9.16 
[The results are expressed as mean ± S.D ] 
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Fig no:15.  Effect of leaf extract on hematological  parameters. (Hb, WBC, RBC). 
       
 
Fig no: 16. Effect of leaf extract on hematological parameters. (PCV, Platelets). 
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7.3.4 Biochemical study 
Determination of biochemical parameters was carried out as per the procedure described in 
materials and methods section 6.3.4.Evaluation of hepatic and renal function is of prime 
importance to assess the inherent toxic properties of drugs. However the results of assay of these 
enzymes revealed no difference between the control and treated group. There were no significant 
changes in the treated group when compared to the control group. The bio-chemical parameters 
of the control and treated group are presented in Table no: 10. 
 Serum Glutamic Oxaloacetic Transaminase (SGOT) 
 Serum Glutamic Pyruvic Transaminase (SGPT) 
 Total cholesterol 
 Triglyeride 
 Protein  
 Creatinine   
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Table no: 10. Effect of leaf extract on bio-chemical parameters. 
Parameters  Control    
group. (n=3) 
   Group – 1 
(minium dose). 
   (n= 3) 
   Group – 2 
(medium dose). 
  (n=3) 
 Group – 3 
 (maximum     
dose). (n=3) 
SGPT (IU/L) 
(International 
unit/ liter) 
103.4 ± 0.45 103.56 ± 1.76 104.73 ± 1.78 102.33 ± 0.47 
SGOT (IU/L) 277.3 ± 0.6 272.3 ± 2.55 279.73 ± 4.65 270.23 ± 0.7 
Total cholesterol 
(mg/dl) 
67.66 ± 0.54 60.63 ± 1.52 73.46 ± 0.90 66.23 ± 0.41 
Triglycerides 
(mg/dl) 
81.16 ± 0.44 79.86 ± 1.07 83.4 ±0.55 79.13 ± 0.60 
Protein (mg/dl) 7.46 ± 0.15 7.26 ± 0.40 7.2 ± 0.35 7.13 ± 0.2 
Creatinine 
(mg/dl) 
0.68 ± 0.03 0.62 ± 0.02 0.64± 0.03 0.66 ± 0.03 
[The results are expressed as mean ± S.D] 
Fig no: 17. Effect of leaf extract on bio-chemical parameters.(SGPT,SGOT,Cholesterol. 
                       
 
0
50
100
150
200
250
300
SGPT SGOT Cholesterol
Group 1
Group 2
Group 3
Control
                                                                                      Results and Discussion 
 
R.V.S College of Pharmaceutical Sciences, Sulur. Page 54 
 
Fig no: 18. Effect of leaf extract on bio-chemical parameters. (Triglyceride, Protein, 
Creatinine). 
                        
 
7.3.5 Gross necropsy and histopathological studies 
Gross necropsy study was carried out as per the procedure described in materials and methods 
section 6.3.5. 
Morphological observation of abdominal cavities, their content, organs like liver, heart and 
kidney were examined and found that there was no sign of inflammation or toxicity in all the 
groups. The results are summarized as follows. 
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                                    Fig no: 19. Histopathological slide of Control group liver. 
 
                      
                            Fig no: 20. Histopathological slide of treated (group – 1) liver.  
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                        Fig no: 21. Histopathological slide of treated (group -2) liver. 
 
 
                   
                        Fig no: 22. Histopathological slide of treated (group – 3) liver. 
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   Fig no: 23. Histopathological slide of control group heart. 
 
            
      Fig no: 24. Histopathological slide of treated (group – 1) heart. 
                                                                                      Results and Discussion 
 
R.V.S College of Pharmaceutical Sciences, Sulur. Page 58 
 
             
        Fig no: 25. Histopathological slide of treated (group – 2) heart. 
 
 
                           
Fig no: 26. Histopathological slide of treated (group- 3) heart.          
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    Fig no: 27. Histopathological slide of control kidney. 
 
 
                         Fig no: 28. Histopathological slide of treated ( group – 1) kidney. 
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    Fig no: 29. Histopathological slide of treated (group – 2) kidney. 
 
      
                           Fig no: 30. Histopathological slide of treated (group - 3) kidney. 
Histopathological study was carried out as per the procedure described in materials and methos 
section  6.3.5. 
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The histopathological investigation of the liver tissue for the control group and treated group 
were examined. The corresponding results are presented in figures 19- 22. Control liver tissue 
pointed out the presence of normal hepatocytes and shown a mild fatty degeneration. The control 
liver cellular architecture was almost retained in treated animals. Hence, it did not show any 
toxicity in the liver. 
The histology of the heart of both the control and treated were shown normal myocardial fiber 
and no significant pathology (shown in figures 23-26). The cellular architecture of the kidney of 
the control and treated groups studied by the histopathological analysis was presented in figures 
27-30. The kidney of the control group showed normal glomeruli and tubules. The 
histopathology of treated kidney when compared with control showed no significant pathology. 
The results of acute toxicity studies clearly demonstrate that the extract treated animals are 
devoid of any toxic sign and indicates that it is safe at the dose of 2000 mg/kg body weight of 
animal. 
7.4 Determination of the thrombolytic activity of the extract  
Determination of thrombolytic activity was carried out as per the procedure given under 
materials and methods section 5.4.The results obtained were significant. The results are given in 
the Table no: 11. 
Table no: 11. Effect of leaf extract/ drug on in-vitro clot lysis 
Extract/Drug Percentage of clot lysis (Mean ± S.D) 
Streptokinase 91.13 ± 1.29 
Water 2.725 ± 0.98 
Ethanolic extract of B.racemosa leaves 90.77 ± 1.67 
DMSO 1.130 ± 0.25 
 
7.5 Compatibility studies of the extract 
7.5.1 Components screening by solubility determination 
The components of formulation were screened for solubility based on the procedure given under 
materials and methods section 6.5.1. 
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The results are as given in the Table no: 12. Acetone was not selected because of its volatile 
nature and methanol was not selected because of its toxic nature.  
Table no: 12. Screening of components for solubility. 
S.NO COMPONENTS SOLUBILITY 
1 OIL: 
Coconut oil  
Neem oil  
Black cumin seed oil  
Cinnamon oil 
Soyabean oil                                                                                                                 
 
Sparingly soluble 
Insoluble 
Sparingly soluble 
Completely soluble 
Sparingly soluble
2 SURFACTANT: 
Tween 80 
Tween 20 
Span80 
 
  Sparingly soluble 
  Insoluble 
  Insoluble 
3 CO-SURFACTANT: 
Ethanol  
Acetone   
methanol   
 
 Completely soluble 
  Soluble 
  Soluble  
 
7.5.2 Drug compatibility studies 
The drug compatibility studies were carried out as per the procedure given under materials and 
methods section 6.5.2.The mixtures were observed for any specific changes. The observations 
are as given below in Table no:13.  
                                            Table no: 13. Drug compatibility study 
NSC – No Specific Change.                                                                                  Wk – Week. 
  
MIX-
TURE 
25±1°C 40±1°C 
1 
Wk 
2 
Wk 
3 
Wk 
4 
Wk 
5 
Wk 
6 
Wk 
7 
Wk 
8 
Wk 
1 
Wk 
2 
Wk 
3 
Wk 
4 
Wk 
5 
Wk 
6 
Wk 
7 
Wk 
8 
Wk 
EXTRAC
T+CINN
AMON 
OIL 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
EXTRAC
T+ETHA
NOL 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
EXTRAC
T+TWEE
N 80 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
 
NSC 
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7.6 Preparation of nanoemulsion of the extract 
The nanoemulsion was prepared as per the procedure given under materials and methods section 
6.6. The step wise procedure for the preparation of nanoemulsion is given in the schematic 
diagram as follows.  
                           Fig no: 31. Schematic representation of preparation steps. 
 
 
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
To the S.mix measured amount of 
oil is added and stirred 
To the above mix add recquired 
amount of water and allowed to stir 
for further  10 mins. 
The nanoemulsion is prepared 
S.mix is formed. 
Weighed quantity of extract is 
dissolved in measured quantity of 
ethanol and stired continuously 
using a magnetic stirrer. 
Approximately weighed quantity of  
Tween 80 (surfactant) added to the 
ethanol mix and stirred continuously 
The emulsion is then sonicated for 
30 minutes. 
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7.7 Characterization of prepared nanoemulsion 
7.7.1 Particle size analysis 
Particle size analysis was carried out as per the procedure given under materials and methods 
section 6.7.1. 
The particle size and size distribution are important for nanoparticles drug delivery. The size 
distribution was given by the polydispersibility index . The lower the value  is the narrow the 
size distribution or the more uniform of the nanoparticles. 
  
 
Fig no: 32. Particle size distribution of the prepared nanoemulsion. 
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7.7.2 Zeta potential determination  
Zeta potential determination was carried out as per the procedure described in materials and 
methods section 6.7.2. 
 The zeta potential represents an index for particle stability. This stability is important in 
preventing aggregation of particles. The zeta potential of the optimized formulation was found to 
be  milli volt (mV). Higher the zeta potential maximum is the stability of nano particles. 
 
            
                               Fig no: 33. Zetapotential of the prepared nanoemulsion. 
7.7.3 Particle morphology study 
Particle morphology study was carried out as per the procedure described in materials and 
methods section 6.7.3. 
The prepared nanoemulsion are subjected to morphological analysis by Scanning Electron 
Microscopy (SEM)  
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Fig no: 34. FESEM imagesof the prepared nanoemulsion. 
7.7.4 In-vitro releae study 
 The release study was carried out as per the procedure described in materials and methods 
section 6.7.4. 
The drug release was slow sustained and dependent upon the drug. Among the nine formulations 
F6  showed the maximum absorbance value during the 12 hr release study. 
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Table no: 14. Release profile of F1 batch. 
 
 
 
 
 
 
 
 
Fig no: 35. Release profile of F1 batch. 
 
 
The drug release profile of F1batch was less when compared to F2 batch. 
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Table no: 15. Release profile of F2 batch. 
 
 
 
 
 
 
 
 
 
Fig no: 36. Release profile of F3 batch 
 
 
 
The drug release profile  was better than F1 batch but comparatively less than F3 batch. 
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Table no: 16. Release profile of F3batch. 
 
 
 
 
 
 
 
 
Fig no: 37. Release profile of F3 batch. 
 
 
The drug release profile was less than F4 batch. 
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                                         Table no: 17. Release profile of F4batch. 
Time in (hrs) Concentration 
0 0 
1 0.055 
2 0.095 
4 0.117 
6 0.123 
8 0.153 
10 0.162 
12 0.168 
  
Fig no: 38. Release profile of F4 batch. 
 
The drug release was uniform but less than F5 batch. 
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                                         Table no: 18. Release profile of F5 Batch. 
Time in (hrs) Concentration 
0 0 
1 0.052 
2 0.083 
4 0.111 
6 0.117 
8 0.123 
10 0.135 
12 0.149 
 
Fig no: 39. Release profile of F5 batch. 
 
                 
The drug release was uniform and good when compared with the earlier batches but less than F6 
batch. 
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Table no: 19. Release profile of F6 batch. 
 
 
 
 
 
 
 
 
Fig no: 40. Release profile of F6 batch. 
 
The release was uniform and good. This batch showed the highest release in the study. 
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Table no: 20. Release profile of F7 batch. 
 
 
 
 
 
                                    
 
 
 
Fig no: 41. Release profile of F7 batch. 
                
The drug release was less when compared to the F6 batch. 
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                                             Table no: 21. Release profile of F8 batch. 
 
 
 
 
 
 
 
 
Fig no: 42. Release profile of F8 batch. 
 
The drug release was uniform but less when compared to the F6 batch. 
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Table no: 22. Release profile of F9 batch. 
 
 
 
 
 
 
 
 
 
Fig no: 43. Release profile of F9 batch. 
 
There was a decline in the release when compared to F6 batch. So, F6 is selected as the 
optimized batch. 
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Table no: 23. Cumulative in-vitro release profile of the prepared nanoemulsion. 
Time in hours 
                      
Concentration 
   F1          F2          F3          F4           F5          F6           F7           F8           F9 
0      0            0            0            0             0            0              0             0             0           
1                        0.035     0.047     0.051     0.055       0.052     0.057      0.054      0.038      0.053     
2                 0.081     0.089     0.090     0.095       0.083     0.098      0.080      0.077      0.090 
4                               0.110     0.113     0.115     0.117       0.111     0.119      0.113      0.112      0.114 
6                                              0.117     0.118     0.120     0.123       0.117     0.125      0.122      0.123      0.121 
8               0.144     0.146     0.149     0.153       0.123     0.155      0.150      0.135      0.151 
10                                         0.152     0.155     0.158     0.162       0.135     0.164      0.155      0.148      0.153 
12                           0.163     0.161     0.165     0.168       0.149     0.170      0.152      0.156      0.164 
 
Fig no: 44. Cumulative in-vitro release profile of the prepared nanoemulsion. 
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7.8 Stability study of nanoemulsion 
 7.8.1 Mechanical stress study 
The stability was determined by the procedure given under materials and method section 6.8.1. 
The different nanoemulsion formulations were assessed for its stability by subjecting them at 
mechanical stress conditions (centrifugation at 2000 rpm). The effect of mechanical stress 
conditions on the physical stability of the nanoemulsion was observed by determining the 
percent phase separation, breaking of nanoemulsion or any physical change. The studies revealed 
that there is no change in the formulations even after 60 mins centrifugation at 2000 rpm. 
Table no: 24. Stability study by mechanical stress method. 
Centrifugation 
time (min)                       
  % phase separated after centrifugation 
F1  F2           F3           F4         F5          F6           F7          F8            F9 
10                                    - -              -             -             -             -             -              -              - 
20                -         -             -              -             -             -             -             -              - 
40               -         -             -              -            -             -              -              -             - 
60 -         -             -              -             -             -             -              -              - 
 
7.8.2 Accelerated temperature study 
Accelerated temperature study was performed to assess the stability of formulations at different 
temperatures by storing the formulations at different temperatures by storing the formulations at 
4 ± 1°C, 25±1°C and 40±1°C for 1, 10, 20 and 30 days and the degree of phase separation or any 
physical change was observed in the formulations. The studies revealed that there is no change in 
the physical state of the nanoemulsion on storing them at 4±1°C and 25±1°C till 30 days but 
breaking of the nanoemulsions was observed at 40±1°C after 10 days of storing. 
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Table no: 25. Stability study by accelerated temperature method. 
Temp/days 
 
% phase separation 
 F1         F2          F3          F4          F5            F6          F7           F8            F9 
4±1°C 
1                                  
10 
20 
30 
 
- -            -             -             -              -              -              -              - 
-         -            -             -             -              -              -              -              - 
-         -            -             -             -              -              -              -              - 
-         -            -             -             -              -              -              -              -        
25±1°C 
1 
10 
20 
30                
 
-         -             -            -             -              -              -              -              - 
-         -             -            -             -              -              -              -              - 
  0.5          0.5         0.5         0.5         0.5          1.0           1.0         1.0           1.0 
  1.0          1.0          1.0        1.5         1.5          1.5           2.0         2.0           2.0    
40±1°C 
1                           
10 
20 
30 
 
   1.0          1.0         1.0         1.0         1.0          1.0           1.0         1.0           1.0 
 
 
           Breaking of nanoemulsion 
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SUMMARY AND CONCLUSION 
The present study was a satisfactory attempt to formulate the nanoemulsion with a view of 
improving the oral bioavailability and thus giving a prolonged release of drug. 
The main objective of the present study was to prepare an nanoemulsion of Bauhinia racemosa 
leaf extract for testing thrombolytic activities. No scientific study was made so far with 
nanoemulsion  for the above activity. 
The leave of Bauhinia racemosa were collected and identified . They were then extracted  with 
ethanol as solvent for 8 hours using soxhlet apparatus by hot continous extraction method. The 
yield was found to be 15.95% w/v. 
Oral acute toxicity was carried out as per OECD guidelines 423 by using rat as an animal model. 
A 2000 mg/kg body weight of animal dose is administered for acute toxicity study. In these 
studies the following parameters were observed for the evaluation of acute toxicity , which 
include gross behavior study, body weight analysis, hematological parameters, bio-chemical 
parameters, gross necropsy and histopathological studies. From the data of the acute toxicity 
studies it clearly demonstrates that the extract was safe up to 2000 mg/kg body weight of animal. 
The thrombolytic activity was carried out by in-vitro method and gave appreciable results. The 
extract showed activity close to that of the standard.  
Compatibility study was carried out by screening the components for solubility by visual 
observations. 
The nanoemulsion was prepared in 9 batches with varying  oil: water ratios like 2:1, 3:1, 4:1. The 
batch that showed a uniform and continuous high release was selected as the optimized batch. F6 
was selected as the optimized batch. 
The other evaluation parameters of nanoemulsion like paricle size, zeta potential, particle 
morphology study was done only for the optimized batch. The particle size and zeta potential 
reports were good. 
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The FESEM images showed good reports but the reports would have been still better with the 
use of Cryo SEM technique. But it is not available in Coimbatore and it takes time to get reports 
from other centers with Cryo SEM. 
The stability study shows satisfactory results. There was no phase separation, breaking of nano 
emulsion or any physical changes in the nanoemulsion during the mechanical stress study. The 
nanoemulsion was stable at the temperature of 4±1°C, 25±1°C.Breaking of nanoemulsion was 
noted at 40±1°C. 
Therefore this study was concluded that the Bauhinia racemosa extract loaded nanoemulsion 
drug delivery is effective for the treatment of thrombosis. 
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